About Exicure
Exicure, Inc. does not have significant operations.
Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.
Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.